Ocugen マネジメント
マネジメント 基準チェック /24
Ocugenの CEO はShankar Musunuriで、 Sep2013年に任命され、 の在任期間は 12.67年です。 の年間総報酬は$ 4.84Mで、 15.7%給与と84.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.5%を直接所有しており、その価値は$ 2.30M 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と5.4年です。
主要情報
Shankar Musunuri
最高経営責任者
US$4.8m
報酬総額
| CEO給与比率 | 15.65% |
| CEO在任期間 | 12.7yrs |
| CEOの所有権 | 0.5% |
| 経営陣の平均在職期間 | 2.1yrs |
| 取締役会の平均在任期間 | 5.4yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.ナラティブの更新 • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.ナラティブの更新 • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.ナラティブの更新 • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Seeking Alpha • Mar 09
Ocugen: Downgrading After OCU410 Data Release
Summary Ocugen (OCGN) is downgraded from 'Buy' to 'Hold' due to concerns over OCU410's dose response in geographic atrophy. Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final ArMaDa data [March 2026], OCU410ST interim [Q3 2026] and topline [Q2 2027], and OCU400 RP topline [Q1 2027]. Company's cash runway extends to Q4 2026 [potentially Q2 2027 with warrant exercise], but quarterly burn and multiple late-stage trial risks remain. Read the full article on Seeking Alphaナラティブの更新 • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.ナラティブの更新 • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.ナラティブの更新 • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.ナラティブの更新 • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.ナラティブの更新 • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.ナラティブの更新 • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.ナラティブの更新 • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.ナラティブの更新 • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.ナラティブの更新 • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.ナラティブの更新 • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
新しいナラティブ • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$72m |
| Dec 31 2025 | US$5m | US$758k | -US$68m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$758k | -US$54m |
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$758k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$8m | US$715k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$8m | US$541k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$500k | -US$34m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$572k | US$420k | -US$20m |
報酬と市場: Shankarの 総報酬 ($USD 4.84M ) は、 US市場 ($USD 2.67M ) の同規模の企業の平均を上回っています。
報酬と収益: Shankarの報酬は増加しましたが、会社は利益を上げていません。
CEO
Shankar Musunuri (61 yo)
12.7yrs
在職期間
US$4,841,822
報酬
Dr. Shankar Musunuri, Ph D., MBA, is Co-Founder of OrthoCellix, Inc. and serves as its Chairman, Chief Executive Officer President and Secretary. Dr. Musunuri is the Co-Founder of Ocugen, Inc. since Septem...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 12.7yrs | US$4.84m | 0.50% $ 2.3m | |
| Chief Accounting Officer & Principal Accounting Officer | 1.6yrs | US$1.19m | 0.00053% $ 2.4k | |
| Chief Scientific Officer and Head of Research & Development | 3.7yrs | US$2.14m | 0.063% $ 291.7k | |
| Chief Medical Officer | 2.2yrs | US$2.89m | 0.0013% $ 6.0k | |
| Chief Financial Officer | less than a year | データなし | 0.15% $ 680.5k | |
| Executive Vice President of Operations | less than a year | データなし | データなし | |
| General Counsel | no data | データなし | データなし | |
| AVP & Head of Corporate Communications | no data | データなし | データなし | |
| Head of People & Culture | 2.1yrs | データなし | データなし | |
| Chief Development Officer | less than a year | US$1.31m | データなし | |
| VP & Head of Regulatory & Quality | 3.3yrs | データなし | データなし | |
| VP, Head of Program Management & Chief of Staff | 2.3yrs | データなし | データなし |
2.1yrs
平均在職期間
52.5yo
平均年齢
経験豊富な経営陣: OCGNの経営陣は 経験豊富 であると考えられます ( 2.1年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 6.7yrs | US$4.84m | 0.50% $ 2.3m | |
| Member of Retina Scientific Advisory Board | 6.5yrs | データなし | データなし | |
| Member of Retina Scientific Advisory Board | no data | データなし | データなし | |
| Vaccine Scientific Advisory Board Member | 5.4yrs | データなし | データなし | |
| Co-founder & Independent Director | 6.7yrs | US$211.25k | 0.21% $ 958.9k | |
| Vaccine Scientific Advisory Board Member | 5.4yrs | データなし | データなし | |
| Independent Director | less than a year | US$182.32k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$196.25k | 0.41% $ 1.9m | |
| Independent Director | 6.1yrs | US$203.75k | 0.022% $ 102.0k | |
| Independent Director | less than a year | US$205.18k | 0% $ 0 | |
| Vaccine Scientific Advisory Board Member | 5.4yrs | データなし | データなし | |
| Chair of Retina Scientific Advisory Board | 2yrs | データなし | データなし |
5.4yrs
平均在職期間
59.5yo
平均年齢
経験豊富なボード: OCGNの 取締役会 は 経験豊富 であると考えられます ( 5.4年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 08:00 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Ocugen, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |